Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2025, SJR score – 0.599, H-index: 54 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

Ahead of print

doi: 10.17219/acem/139917

Publication type: experimental paper

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation on quality of life and progression-free survival in patients with pancreatic cancer: IREC clinical study

Julia Rudno-Rudzińska1,A,B,C,D,E, Wojciech Kielan2,A,B,F, Maciej Guziński1,B, Julita Kulbacka3,A,E,F

1 2nd Department of General and Oncological Surgery, Wroclaw Medical University, Poland

2 Department of Radiology, Wroclaw Medical University, Poland

3 Department of Molecular and Cellular Biology, Wroclaw Medical University, Poland

Abstract

Background. According to the National Cancer Registry, 3486 people (1744 men and 1742 women) were diagnosed with pancreatic adenocarcinoma in Poland in 2018, resulting in 4908 deaths (2396 men and 2512 women). The only chance of successful treatment is through surgical resection, which is possible in only 20–30% of patients (stage I, II and some stage III cases).The remaining 70–80% of patients are those with stage III and IV disease, for whom resection is not possible. Mean survival in these patients is approx. 10.4 months (stage III). In the recent decade, an innovative method called electroporation, which involves destabilization of the cell membrane, has been established. This process can be reversible (RE) or irreversible (IRE), and leads to cell death. The ability to change membrane permeability has led to the development of novel methods involving electrochemotherapy (ECT) and calcium electroporation (CaEP) to treat solid tumors.
Objectives. In this study, both ECT and CaEP will be used to treat pancreatic cancer patients with poor prognosis. For each patient, the best “therapeutic moment” for the procedure will be selected based on the therapeutic protocol.
Material and Methods. Patients will receive reversible and irreversible electroporation (control arm-group A), CaEP (active arm-group B), or ECT with intravenous and intratumoral administration of bleomycin (active arm-group C) randomized 1:1:1.
Results. The primary endpoints will be progression-free survival (PFS) and patients’ quality of life (QOL) assessed using the EORTC-PAN 26 scale. Secondary endpoints will be patient overall survival (OS), body weight, pain level, and levels of biomarkers such as Ca 19-9.
Conclusion. The Irreversible Electroporation, ELectrochemotherapy and Calcium electroporation (IREC) study is necessary to examine the safety and efficiency of irreversible electroporation, electrochemotherapy and calcium electroporation in pancreatic cancer treatment.

Key words

pancreatic cancer, electroporation, electrochemotherapy, calcium electroporation

References (53)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
  2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155
  3. Quante AS, Ming C, Rottmann M, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649–2656. doi:10.1002/cam4.767
  4. Klaiber U, Leonhardt CS, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg. 2018;403(8):917–932. doi:10.1007/s00423-018-1724-8
  5. Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant treatment for pancreatic cancer. Semin Oncol. 2019;46(1):19–27. doi:10.1053/j.seminoncol.2018.12.002
  6. Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial. JAMA Oncol. 2019;5(7):1020–1027. doi:10.1001/jamaoncol.2019.0892
  7. Venkatesulu BP, Hsieh CE, Sanders KL, Krishnan S. Recent advances in radiation therapy of pancreatic cancer. F1000Res. 2018;7:F1000 Faculty Rev-1931. doi:10.12688/f1000research.16272.1
  8. Daniels C, Rubinsky B. Electrical field and temperature model of nonthermal irreversible electroporation in heterogeneous tissues. J Biomech Eng. 2009;131(7):071006. doi:10.1115/1.3156808
  9. Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: Irreversible electroporation. Radiology. 2010;255(2):426–433. doi:10.1148/radiol.10090337
  10. Lee EW, Thai S, Kee ST. Irreversible electroporation: A novel image-guided cancer therapy. Gut Liver. 2010;4(Suppl 1):S99–S104. doi:10.5009/gnl.2010.4.S1.S99
  11. Maor E, Rubinsky B. Endovascular nonthermal irreversible electroporation: A finite element analysis. J Biomech Eng. 2010;132(3):031008. doi:10.1115/1.4001035
  12. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456–1462. doi:10.1126/science.7878464
  13. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochodrial apoptosis-inducing factor. Nature. 1999;397(6718):441–446. doi:10.1038/17135
  14. Lambert L, Horejs J, Krska Z, et al. Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: General hospital cancer center experience. Neoplasma. 2016;63(2):269–273. doi:10.4149/213_150611N326
  15. Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611–621. doi:10.1016/j.jvir.2010.12.014
  16. Onik G, Mikus P, Rubinsky B. Irreversible electroporation: Implications for prostate ablation. Technol Cancer Res Treat. 2007;6(4):295–300. doi:10.1177/153303460700600405
  17. Martin RCG, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: Potential improved overall survival. Ann Surg Oncol. 2013;20(3 Suppl):S443–S449. doi:10.1245/s10434-012-2736-1
  18. Campana LG, Edhemovic I, Soden D, et al. Electrochemotherapy: Emerging applications technical advances, new indications, combined approaches, and multi-institutional collaboration. Eur J Surg Oncol. 2019;45(2):92–102. doi:10.1016/j.ejso.2018.11.023
  19. Gehl J. Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand. 2003;177(4):437–447. doi:10.1046/j.1365-201X.2003.01093.x
  20. Mir LM, Orlowski S, Belehradek J, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer Clin Oncol. 1991;27(1):68–72. doi:10.1016/0277-5379(91)90064-K
  21. Girelli R, Prejanò S, Cataldo I, et al. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: A pre-clinical investigation. Radiol Oncol. 2015;49(2):147–154. doi:10.1515/raon-2015-0013
  22. Falk H, Lambaa S, Johannesen HH, Wooler G, Venzo A, Gehl J. Electrochemotherapy and calcium electroporation inducing a systemic immune response with local and distant remission of tumors in a patient with malignant melanoma: A case report. Acta Oncol. 2017;56(8):1126–1131. doi:10.1080/0284186X.2017.1290274
  23. Zhang Z, Li W, Procissi D, Tyler P, Omary RA, Larson AC. Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. Nanomedicine. 2014;9(8):1181–1192. doi:10.2217/nnm.13.72
  24. Serša G, Jarm T, Kotnik T, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer. 2008;98(2):388–398. doi:10.1038/sj.bjc.6604168
  25. Serša G, Beravs K, Čemažar M, Miklavčič D, Demsar F. Contrast enhanced MRI assessment of tumor blood volume after application of electric pulses. Electromagn Biol Med. 1998;17(2):299–306. doi:10.3109/15368379809022574
  26. Serša G, Cemazar M, Miklavcic D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res. 1999;19(5B):4017–4022. PMID:10628347
  27. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931. doi:10.1056/NEJMoa1112824
  28. Caracò C, Mozzillo N, Marone U, et al. Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer. 2013;13:564. doi:10.1186/1471-2407-13-564
  29. Kunte C, Letulé V, Gehl J, et al. Electrochemotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT. Br J Dermatol. 2017;176(6):1475–1485. doi:10.1111/bjd.15340
  30. Mir LM, Orlowski S, Poddevin B, Belehradek JJ. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defenses. Eur Cytokine Netw. 1992;3(3):331–334. PMID:1379837
  31. Serša G, Čemažar M, Menart V, Gaberc-Porekar V, Miklavčič D. Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-α on SA-1 tumors in mice. Cancer Lett. 1997;116(1):85–92. doi:10.1016/S0304-3835(97)00170-5
  32. Gerlini G, Di Gennaro P, Borgognoni L. Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology. 2012;1(9):1655–1657. doi:10.4161/onci.21991
  33. Kos B, Voigt P, Miklavcic D, Moche M. Careful treatment planning enables safe ablation of liver tumors adjacent to major blood vessels by percutaneous irreversible electroporation (IRE). Radiol Oncol. 2015;49(3):234–241. doi:10.1515/raon-2015-0031
  34. Carafoli E, Santella L, Branca D, Brini M. Generation, control, and processing of cellular calcium signals. Crit Rev Biochem Mol Biol. 2001;36(2):107–260. doi:10.1080/20014091074183
  35. Berridge MJ, Bootman MD, Roderick HL. Calcium signaling: Dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517–529. doi:10.1038/nrm1155
  36. Frandsen SK, Gissel H, Hojman P, Tramm T, Eriksen J, Gehl J. Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis. Cancer Res. 2012;72(6):1336–1341. doi:10.1158/0008-5472.CAN-11-3782
  37. Frandsen SK, Gehl J. Effect of calcium electroporation in combination with metformin in vivo and correlation between viability and intracellular ATP level after calcium electroporation in vitro. PLoS One. 2017;12(7):e0181839. doi:10.1371/journal.pone.0181839
  38. Hansen EL, Sozer EB, Romeo S, Frandsen SK, Vernier PT, Gehl J. Dose-dependent ATP depletion and cancer cell death following calcium electroporation, relative effect of calcium concentration and electric field strength. PLoS One. 2015;10(4):e0122973. doi:10.1371/journal.pone.0122973
  39. Calvet CY, Famin D, André FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology. 2014;3:e28131. doi:10.4161/onci.28131
  40. Plaschke CC, Gehl J, Johannesen HH, et al. Calcium electroporation for recurrent head and neck cancer: A clinical phase I study. Laryngo­scope Investig Otolaryngol. 2019;4(1):49–56. doi:10.1002/lio2.233
  41. Rudno-Rudzińska J, Kielan W, Guziński M, Płochocki M, Kulbacka J. The first study of irreversible electroporation with calcium ions and chemotherapy in patients with locally advanced pancreatic adenocarcinoma. Appl Sci. 2020;10(15):5163. doi:10.3390/app10155163
  42. Mir LM, Gehl J, Sersa G, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator TM by means of invasive or non-invasive electrodes. EJC Suppl. 2006;4(4):14–25. doi:10.1016/j.ejcsup.2006.08.003
  43. Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: Clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol. 2009;16(1):191–199. doi:10.1245/s10434-008-0204-8
  44. Gargiulo M, Papa A, Capasso P, Moio M, Cubicciotti E, Parascandolo S. Electrochemotherapy for non-melanoma head and neck cancers: Clinical outcomes in 25 patients. Ann Surg. 2012;255(6):1158–1164. doi:10.1097/SLA.0b013e31824f68b2
  45. National Institute for Health and Care Excellence (NICE). Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. https://www.nice.org.uk/guidance/ipg478. Published February 26, 2014.
  46. National Institute for Health and Care Excellence (NICE). Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. https://www.nice.org.uk/guidance/ipg446. Published March 27, 2013.
  47. Schmidt G, Juhasz-Böss I, Solomayer EF, Herr D. Electrochemotherapy in breast cancer: A review of references. Geburtshilfe Frauenheilkd. 2014;74(6):557–562. doi:10.1055/s-0034-1368538
  48. Miklavčič D, Mali B, Kos B, Heller R, Serša G. Electrochemotherapy: From the drawing board into medical practice. Biomed Eng Online. 2014;13(1):29. doi:10.1186/1475-925X-13-29
  49. Bimonte S, Leongito M, Granata V, et al. Electrochemotherapy in pancreatic adenocarcinoma treatment: Pre-clinical and clinical studies. Radiol Oncol. 2016;50(1):14. doi:10.1515/raon-2016-0003
  50. Jaroszeski MJ, Illingworth P, Pottinger C, Hyacinthe M, Heller R. Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model. Anticancer Res. 1999;19(2A):989–994. PMID:10368643
  51. Granata V, Fusco R, Piccirillo M, et al. Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int J Surg. 2015;18:230–236. doi:10.1016/j.ijsu.2015.04.055
  52. Tafuto S, von Arx C, De Divitiis C, et al. Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases. Int J Surg. 2015;21(Suppl 1):S78–S82. doi:10.1016/j.ijsu.2015.04.095
  53. Edhemovic I, Gadzijev EM, Brecelj E, et al. Electrochemotherapy: A new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat. 2011;10(5):475–485. doi:10.7785/tcrt.2012.500224
© Wroclaw Medical University